ALB and neoplasm: The tumor-to-kidney dose ratio of [177Lu]Lu-PSMA-617 was higher than that of the albumin-binding radioligands, but the absolute value of the mean absorbed tumor dose of [177Lu]Lu-PSMA-617 remained relatively low in comparison to the new radioligands.